Download Files:
AG-13958
$202 – $3,700
Products Details
Product Description
– AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD)[1].
Web ID
– HY-15492
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C26H22FN7O
References
– [1]Solowiej J, et al. Substrate-specific conformational regulation of the receptor tyrosine kinase VEGFR2 catalytic domain. ACS Chem Biol. 2013 May 17;8(5):978-86.|[2]M.B. Kosa, et al. Ocular and Systemic Pharmacokinetics of AG-013958 With Sub-Tenon Administration To Cynomologus Monkeys. Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5379.
CAS Number
– 319460-94-1
Molecular Weight
– 467.50
Compound Purity
– 99.71
SMILES
– O=C(C1=CC(C)=NN1C)NC2=CC(NC3=CC4=C(C=C3)C(/C=C/C5=NC=CC=C5)=NN4)=CC=C2F
Clinical Information
– No Development Reported
Research Area
– Cardiovascular Disease
Solubility
– DMSO : 5 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– VEGFR
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
